XRTX: xortx.com Cash Calculated per Single Share

XORTX Therapeutics Inc. (XRTX) is implementing "green chemistry" principles to make its laboratories more environmentally friendly. The change in cash per share shown on this GURU.Markets chart confirms financial stability, where 0.18 captures the current value of the indicator. Strong pricing power is based on oxypurinol patents, while long-term development relies on growing demand from clinics in the kidney therapy segment.
Comprehensive metric breakdowns and analytics for XORTX Therapeutics (XRTX)

XORTX Therapeutics Inc. (XRTX) invests in the development of uric acid suppression methods to protect kidney tissues. Mathematically, these expenditures are reflected through the difference between liquid assets and debts, divided by the number of shares. This metric measures the actual reserve of "live" cash per share, determining the issuer's financial stability. The current value of 0.18 allows for an assessment of the opportunity cost risk. The dynamics of cash per security highlight hidden tail risks.